Status:
UNKNOWN
Methotrexate Versus Triamcinilone Acetonide in Treatment of Recalcitrant Alopecia Areata
Lead Sponsor:
Al-Azhar University
Conditions:
Alopecia Areata
Eligibility:
All Genders
12+ years
Phase:
NA
Brief Summary
Alopecia areata is the second most common cause of hair loss following androgenic alopecia. It is affecting 2% of global population with an increasing prevalence. Briefly, it is a chronic, immunomedi...
Eligibility Criteria
Inclusion
- Age groups: \> 12 years old.
- Sex: both sexes.
- Co-operative Patients.
- Recalcitrant or resistant cases to treatment (meaning that all patients had received various modalities of treatment in the past with poor/partial response or relapse after discontinuing therapy.
Exclusion
- Patients \<12 years.
- Pregnant and lactating women.
- Patients with any underlying Systemic disorders.
- Patients with HBV or HCV.
- Patient with active infection of T.B.
- Patients with bone marrow suppression (leukopenia, thrombocytopenia)
- Patients who had received any other modalities of treatment in last 3-6 months.
Key Trial Info
Start Date :
December 1 2023
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
June 1 2024
Estimated Enrollment :
34 Patients enrolled
Trial Details
Trial ID
NCT06088147
Start Date
December 1 2023
End Date
June 1 2024
Last Update
November 13 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Al-Azhar University
Asyut, Egypt